Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aveo Pharmaceuticals Inc (NASDAQ:AVEO)

0.7855
Delayed Data
As of Feb 24
 -0.027 / -3.32%
Today’s Change
0.54
Today|||52-Week Range
1.23
+45.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$59.6M

Company Description

AVEO Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the advancement of therapeutics for oncology and other areas of unmet medical need. Its products include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. It focuses on the development of its lead candidate, Tivozanib, in North America as a treatment for renal cell carcinoma and other cancers. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Contact Information

AVEO Pharmaceuticals, Inc.
One Broadway
Cambridge Massachusetts 02142
P:(617) 588-1960
Investor Relations:

Employees

Shareholders

Mutual fund holders4.37%
Individual stakeholders23.42%
Other institutional16.71%

Top Executives

Michael P. BaileyPresident, Chief Executive Officer & Director
Keith S. EhrlichChief Financial Officer
Emile FarhanVice President-Technical Operations
Michael N. NeedleChief Medical Officer
Karuna RubinSecretary, Head-Legal Affairs & Compliance